CuraGenix Life Sciences


Life Sciences



Creating a healthier tomorrow


Dedicated to delivering accessible, high-quality medicines, our mission is to improve global health outcomes by providing cost-effective innovative medications that meet the diverse, unmet needs of patients and healthcare systems. We achieve this through innovation, ethical practices, and a relentless commitment to quality and affordability.

Please get in touch with us, we are seeking new partners


Branded acquisitions & licensing


Generic licensing & development


Product innovations & development

We Take Care

CuraGenix life sciences is part of the CST group spending over 20 years to since 2002 in wholesale, retail, consumer products, specials supply, medical devices, we are thrilled to announce our new business segment into the Pharmaceutical and biological business.

We have track record of timely development and registration, along with strategic and effective marketing across the globe.

Why Choose CuraGenix

Our Key Therapy

Orphan Diseases
Anti Infectives
Central Nervous System

What Our Customers Say

Sed odio donec curabitur auctor amet tincidunt non odio enim felis tincidunt amet morbi egestas hendrerit.
Jennifer Lewis
Sed odio donec curabitur auctor amet tincidunt non odio enim felis tincidunt amet morbi egestas hendrerit.
Alicia Heart
Sed odio donec curabitur auctor amet tincidunt non odio enim felis tincidunt amet morbi egestas hendrerit.
Juan Carlos

Latest News

Lorem ipsum dolor

Nullam condimentum tristique ipsum iaculis dignissim. Proin non ligula non...

News lorem

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sagittis...


If you have experienced a suspected side effect while taking our product please discuss this with your doctor, nurse or pharmacist. To report a suspected side effect or if you have a query regarding one of our products please contact us



+44 1477 536 061

Secure Payment

Curabitur interdum, nisl at tincidunt.

Delivered With Care

Donec sit amet neque id nisl.

Excellent Service

Amet neque id nisl ullamcorper.

Jason Yates

a seasoned leader and Managing Director of the CST Group of companies. With over two decades of experience in the healthcare and pharmaceutical industry, Jason has a proven track record of driving strategic initiatives, optimizing operations, and fostering strong relationships with suppliers and stakeholders. Jason is committed to innovation, growth, and ensuring the delivery of vital pharmaceuticals to healthcare providers across the world

Carl Falzon

is a dynamic and results-driven Commercial Director with a robust background in the pharmaceutical industry. With a career spanning over 20 years, Carl has displayed expertise in developing and executing commercial strategies that drive business growth and market expansion. His leadership has been instrumental in forging successful partnerships, negotiating key contracts, and implementing innovative sales and marketing initiatives to enhance market presence. Carl's sharp business acumen, coupled with a deep understanding of market dynamics, has consistently contributed to the success and profitability of the company's commercial operations, positioning the firm as a prominent player in the pharmaceutical sector.

Jonathan Dally

Jonathan is Our head of Business Development / Business Intelligence and Clinical Affairs has over 25 years of UK Pharma experience, covering various sectors including Clinical Trials, NHS tenders, Trade mark registration, Business Intelligence/ Business Development  and Clinical Affairs. He has a proven history of successfully managing several national / international clinical trials and more recently he has been hugely successful in attaining numerous NHS tender awards since 2018, including several National NHS Framework Agreement tender awards.  Furthermore, he is an author of academic and clinical trial-based publications,  As a leader and driver of business project programmes through effective project management, in accordance with the Company's processes, he has successfully collaborated with EU partners leading to the uptake of newly approved generic lines by the NHS (in both retail and hospital markets) and the regulatory submission of a new product line to the MHRA. In his current role, he provides science-based and clinical-based advice to the Senior Management Team/Board regarding in—licensing opportunities and acquisitions, as well as for collaborations with potential commercial partners wishing to sell licenced medicines, food supplements and medical devices in the UK.  He also performs due diligence reviews of potential product acquisitions / partnership opportunities and he works directly with contractors in order to ensure on-time and cost-effective delivery of high-quality output. He holds a BSc (Hons) degree in Pharmacology from Bath University and a Doctor of Philosophy (DPhil) degree from the University of Oxford.